Johnson & Johnson
NYSE:JNJ
Johnson & Johnson
NYSE:JNJ
Price:
148.58 USD
-0.46%
Market Closed
Updated:
May 7, 2024
Johnson & Johnson
Operating Income
|
Johnson & Johnson
Operating Income Peer Comparison
Comparables:
BMY
PFE
MRK
ZTS
LLY
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$24.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$10.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-5%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-3%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Operating Income
$3.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$11.3B
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
See Also
What is Johnson & Johnson's Operating Income?
Operating Income
24.3B
USD
24.3B
USD
Based on the financial report for Mar 31, 2024, Johnson & Johnson's Operating Income amounts to 24.3B USD.
What is Johnson & Johnson's Operating Income growth rate?
Operating Income CAGR 10Y
3%
3%
Over the last year, the Operating Income growth was 13%. The average annual Operating Income growth rates for Johnson & Johnson have been 4% over the past three years , 4% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet
